

ORIGINAL ARTICLE

Imbalance of Follicular Double Positive and Follicular Double Negative T cells in Ulcerative Colitis Patients

¹Khadega N. Zyada, ²Omnia El-Badawy, ³Asmaa M. Zahran, ⁴Mohammed A. Medhat, ⁴Ahmad S. Abdelmohsen, ²Mohamed S. Badary, ²Ragaa S. Rashwan*

¹Microbiology and Immunology Department of, Faculty of Pharmacy, Assiut University, Assiut, Egypt

²Medical Microbiology and Immunology Department, Faculty of Medicine, Assiut University, Assiut, Egypt

³Clinical Pathology Department, South Egypt Cancer Institute, Assiut University

⁴Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt

ABSTRACT

Key words:

Ulcerative Colitis; DP T cell; DN T cell; Follicular; Flow Cytometry

***Corresponding Author:**

Ragaa Sedeik Rashwan,
Department of Medical
Microbiology and Immunology,
Faculty of Medicine, Assiut
University, Assiut-Egypt.
ragaa.sedeik@aun.edu.eg

Background: Double-positive (DP) and double-negative (DN) thymocytes are well-characterized stages of T cell development in the thymus. Disturbances in their levels have been previously observed in chronic inflammatory diseases and autoimmune disorders. **Objective:** This study aimed to analyze follicular DP and DN T cell levels in ulcerative colitis patients' peripheral blood and colon tissue biopsy and determine whether their levels correlate with disease severity. **Methodology:** This study involved 22 patients with ulcerative colitis (UC) and 18 healthy controls. Flow cytometry was used to measure the total levels of DP and DN T cells and their subsets in each participant's peripheral blood and colon tissue biopsy. **Results:** DP T cells were higher in tissue than in the blood samples. DN T cells were lower in tissue than the blood but higher in patients than control tissues. Differences were observed in the tissue levels of follicular DP and DN cells and their expression levels of CD154 compared with blood and in severe compared with non-severe cases. **Conclusion:** Levels of DP and DN follicular T cells are higher in the tissue of UC patients than in blood, with higher expression of CD154 in tissues. Levels of these cells are higher in more severe cases and show good efficiencies in predicting disease severity. Further research is needed to assess whether these cells have a role in the inflammatory process in UC.

INTRODUCTION

Inflammatory bowel diseases (IBD) are a group of recurrent, long-term inflammatory diseases of the gastrointestinal system. The two main types of inflammatory bowel disease (IBD) are ulcerative colitis (UC) and Crohn's disease as reported by Spiceland et al.¹, Al-Bawardy et al.², Zhang et al.³

Studies indicate that aberrant interactions between T cells and other immune and non-immune cells are crucial in promoting the pathological processes of UC, even if the etiology and pathogenic processes of the disease are still unclear. T cell-derived cytokines are crucial mediators of these interactions.⁴

Before developing into either CD4+ or CD8+ (single positive) mature T cells, CD4+CD8+ double positive (DP) T cells were considered a developmental stage in the thymus. As a result, most T cells in peripheral blood and tissues have only expressed one of these co-receptors, which correlates to distinct functions. CD4 T cells serve as helpers in the immune response, while CD8 T cells primarily cytotoxically attack tumors or infected cells.⁵

Mature DP T cells, however, have been seen in peripheral blood and tissues in various contexts, including human malignancies. The contradicting research on the cytotoxic vs. immunosuppressive roles of DP T cells may suggest that these cells are diverse and/or have pleiotropic functions, which need further study in the context of each disease.⁵ There's no hard evidence, but it's possible that poor thymic selection gave rise to auto-reactivity in CD4(hi) and CD8(hi) T cells.⁶

Some mature peripheral T cells are double-negative (DN) T cells. The origin and functions of DN T cells are a topic of discussion and not entirely established. While DN T cells in healthy individuals resemble a rare and heterogeneous T cell subpopulation, under several inflammatory conditions, the frequency of TCRαβ+ DN T cells is increased, and they also show different effector attitudes and infiltrate inflammatory tissues.⁷ DN T cells can function as regulatory T cells (Tregs), which may prevent autoimmune diabetes, graft-versus-host disease, and allograft rejection.⁸

Chemokine receptor type 5 (CXCR5) plays a role in developing the B cell compartment and directing lymphocyte traffic within secondary lymphoid tissues.

Mice with deleted CXCR5 gene exhibit impaired B cell trafficking, inguinal node, Peyer's patch, and germinal center formation.⁹ CD40 ligand (CD40L or CD154), a type II membrane protein transiently expressed on activated T cells and resembling TNF, plays a crucial role in B cell Ig synthesis, as well as in the activation and differentiation of monocytes and dendritic cells. Local synthesis of cytokines like TNF and an influx of activated lymphocytes into inflamed mucosa are characteristics of both Crohn's disease and ulcerative colitis.¹⁰

However, the contribution of CXCR5+CD4+CD8+ (follicular DP) and CXCR5+CD4-CD8- (follicular DN) T cells to the development of UC is so far lacking.

This study aimed to analyze the follicular DP and DN T cell levels in UC patient's peripheral blood and colon tissue biopsy compared with a control group and determine whether their levels correlate with disease severity.

METHODOLOGY

Study Design:

This case-control study was carried out from June 2022 to May 2023, at the Flow Cytometry Laboratory, South Egypt Cancer Institute, in collaboration with the Medical Microbiology & Immunology Department, Faculty of Medicine, Assiut University.

The study included 22 UC patients admitted to the Tropical Medicine and Gastroenterology Department, Al-Rajhi Liver Hospital, Assiut University. Inclusion criteria: Patients who diagnosed as IBD, based on clinical manifestation, radiographic, endoscopic, and histological criteria were included in the study. Exclusion criteria: Pregnant patients and patients having colorectal or any other cancers, intestinal parasitic infection, indeterminate colitis or Crohn's disease, patients receiving cyclosporine, non-steroidal anti-inflammatory drugs (NSAID), or any antibiotics within the last two weeks, and patients receiving any glucocorticoids or immunosuppressant within the previous three months were excluded from the study.

Also, 18 sex and age-matched healthy cases were enrolled as a control group. The control group was chosen from cases without clinical symptoms or signs associated with ulcerative colitis. Their endoscopic examination was normal and their serological marker for UC (ANCA, antineutrophil cytoplasmic antibody) was negative.

Complete history assessment and clinical examination were performed for all participants, including monitoring of vital signs, a dermatological, articular, and ophthalmological examination to check for extra intestinal manifestations of UC, an extensive abdominal examination, and a colonoscopy.

The Mayo Clinic scoring system was utilized to measure disease activity in UC patients. Rectal

bleeding, stool frequency, physician assessment, and endoscopic appearance are the four components of this examination. A score of 3 to 5 indicates mildly active disease, 6 to 10 indicates moderately active disease, and a score of 11 to 12 indicates severely active disease¹¹. All participants voluntarily gave written informed consent.

Complete blood count (CBC) was done for all participants, and the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and neutrophil-to-platelet ratio (NPR) were calculated. These ratios are considered biomarkers for diagnosing and assessing disease activity in UC^{12, 13, 14}.

The Assiut University Faculty of Medicine's Medical Ethics Committee approved the study protocol (IRB no. 17101694).

Sample Collection and Processing

To evaluate the percentages of follicular DP and follicular DN T cells in human peripheral blood and the colon of patients with active UC compared to controls, two milliliters of whole blood samples and fresh colon tissue biopsy were collected from all participants and subjected to flow cytometry analysis.

A fresh tissue sample was transferred to a Petri dish and washed with 3 ml PBS (PH 7.4). Next, PBS was discarded, one ml PBS was added to the tissue, and the tissue was ground using a sharp scalpel. After proper tissue grinding, suspension (PBS with cells from tissue) was transferred into a 5 ml falcon tube. The tube was centrifuged at 2500 rpm for 1 min, and the supernatant was discarded. The tissue cell pellet was resuspended in 1 ml PBS, and a 40-micron Falcon mesh filtered the suspension.

Flow Cytometry Analysis

A five-color flow cytometry analysis was carried out using a set of fluorochrome-labeled monoclonal antibodies against the surface markers [Phycoerythrin (PE)-conjugated anti-ICOS, Allophycocyanin (APC)-conjugated anti-CXCR5, APC-H7-conjugated anti-CD8, Fluorescein 6-isothiocyanate (FITC)-conjugated anti-CD154, Peridinin-Chlorophyll-Protein Cyanine 5.5 (PerCP-Cy5.5)-conjugated anti-CD4].

One hundred microliters of whole blood and one hundred micrograms of tissue were transferred into clean test tubes, and an RBC lysing solution was added. Then centrifugation was done at 2000 r.p.m for 1 min, and the supernatant was discarded. The pellet was resuspended in 1 ml phosphate-buffered saline (PBS). After centrifugation, ten microliters of each monoclonal antibody were added to the pellet, and the mixture was incubated for 15 min at 4°C in the dark. Appropriate isotype controls were also prepared and processed similarly without adding the T cell monoclonal antibodies. Flow cytometric analysis was performed by the Becton Dickinson Biosciences (BD) fluorescence-activated cell sorter (FACSCanto II) using the FACS

DIVA software (BD, USA). A minimum of 50000 events were collected for each sample analysis. Isotype control staining was used to exclude the nonspecific fluorescence.

Statistical Analysis

SPSS (Statistical Package for the Social Science, version 20, IBM, USA) was used to analyze the data. The Shapiro test was employed to determine if the data adhered to a normal distribution. Data was represented as mean \pm standard deviation (SD). When comparing quantitative data with a normal distribution, the Student t-test was used. Number (n) and percentage (%) represented nominal data. Chi² testing was applied to this kind of data. Because the 95% confidence level was maintained, a *P* value was deemed significant if it was less than 0.05.

RESULTS

Demographic data of UC-infected patients:

Regarding mean age and sex, there were no significant differences between the two groups. The mean age of UC patients was 36.4 \pm 13.8 years compared to 34.4 \pm 12.0 years in the control group (*p* = 0.6). Fourteen patients (63.6%) were females, while 8

(36.8%) were males. On the other hand, 11 controls (61%) were females, and 7 (39%) were males (*p* = 0.87). It was found that 13 (59.1%) patients had mild/moderate disease severity, while 9 (40.9%) patients had severe disease.

Characterization of DP and DN T cell subsets in the studied groups in blood and colon tissue samples compared to controls

For blood samples, as shown in Table (1), the total level of DP T cells was higher in the UC patient group than in healthy controls (*p* = 0.02). While there was no significant difference in the percentage of active follicular DP T cells, their CD154 expression level was lower in UC patients than in controls (*p* = 0.007). Meanwhile, the frequency of active non-follicular DP T cells was higher in the UC patient group (*p* = 0.001), with no difference in their CD154 expression levels.

For DN T cells, there was no significant difference in either the total level of DN T cells or the active follicular DN T cells between both groups. On the other hand, active non-follicular DN T cells were higher in UC patients (*p* = 0.001). The expression of CD154 among both active follicular and active non-follicular DN T cells was lower in UC patients than HC (*p* < 0.0001 and 0.013, respectively).

Table 1: Comparison of the levels of double-positive (DP) and double-negative (DN) T cell subsets in blood samples of patients and controls

| Cells | Patient group (n= 22) | Control group (n= 18) | <i>p</i> -value |
|----------------------------------|-----------------------|-----------------------|-----------------|
| Lymphocytes | 29.67 \pm 5.46 | 39.06 \pm 8.24 | <0.0001 |
| CD4+CD8+ (DP) T cells (%) | | | |
| Total DP | 0.37 \pm 0.11 | 0.29 \pm 0.09 | 0.02* |
| ICOS+CXCR5+ DP | 32.54 \pm 9.11 | 27.89 \pm 7.75 | 0.095 |
| ICOS+CXCR5+CD154+ DP | 27.80 \pm 5.67 | 33.46 \pm 6.90 | 0.007* |
| ICOS-CXCR5+ DP | 12.42 \pm 3.61 | 14.33 \pm 3.47 | 0.098 |
| ICOS-CXCR5+CD154+ DP | 48.45 \pm 13.85 | 36.04 \pm 11.24 | 0.005* |
| ICOS+CXCR5- DP | 51.00 \pm 15.28 | 34.67 \pm 11.05 | 0.001* |
| ICOS+CXCR5-CD154+ DP | 7.01 \pm 2.36 | 6.85 \pm 1.87 | 0.819 |
| ICOS-CXCR5- DP | 23.99 \pm 7.63 | 37.80 \pm 11.53 | <0.0001 |
| ICOS-CXCR5- CD154+ DP | 40.32 \pm 12.10 | 50.88 \pm 13.22 | 0.014* |
| CD4-CD8- (DN) T cells (%) | | | |
| Total DN | 50.38 \pm 11.55 | 55.63 \pm 7.23 | 0.102 |
| ICOS+CXCR5+ DN | 1.95 \pm 0.63 | 1.82 \pm 0.47 | 0.456 |
| ICOS+CXCR5+CD154+ DN | 22.57 \pm 6.92 | 37.88 \pm 10.61 | <0.0001 |
| ICOS-CXCR5+ DN | 20.24 \pm 6.54 | 7.01 \pm 2.21 | <0.0001 |
| ICOS-CXCR5+CD154+ DN | 7.10 \pm 1.60 | 13.65 \pm 3.90 | <0.0001 |
| ICOS+CXCR5- DN | 22.39 \pm 7.25 | 15.45 \pm 4.33 | <0.0001 |
| ICOS+CXCR5-CD154+ DN | 10.03 \pm 3.31 | 12.91 \pm 3.68 | 0.013* |
| ICOS-CXCR5- DN | 26.61 \pm 5.61 | 31.62 \pm 6.43 | 0.012* |
| ICOS-CXCR5-CD154+ DN | 16.54 \pm 4.99 | 20.11 \pm 6.47 | 0.056 |

As shown in Table (2), for colon tissue, the level of active non-follicular DP T cells was higher in UC patients than in controls ($p < 0.0001$). At the same time, there were no significant differences in the total DP T cells or the other DP T cell subsets. The total level of DN T cells was higher in UC patients than HC

($p = 0.007^*$). The level of active non-follicular DN T cells expressing CD154 was lower in UC patients than in controls ($p = 0.007$). Other DN T cell subsets showed no significant differences between the two groups (table 2).

Table 2: Comparison of the levels of double-positive (DP) and double-negative (DN) T cell subsets in colon tissue samples of patients and controls

| Cells | Study group (n= 22) | Control group (n= 18) | P value |
|----------------------------------|---------------------|-----------------------|---------|
| Lymphocytes | 44.72 \pm 9.25 | 45.08 \pm 9.21 | 0.903 |
| CD4+CD8+ (DP) T cells (%) | | | |
| Total DP | 23.40 \pm 7.71 | 27.34 \pm 7.46 | 0.111 |
| ICOS+CXCR5+ DP | 72.62 \pm 10.81 | 75.55 \pm 7.43 | 0.336 |
| ICOS+CXCR5+CD154+ DP | 98.21 \pm 3.23 | 98.34 \pm 5.17 | 0.923 |
| ICOS-CXCR5+ DP | 2.85 \pm 0.86 | 3.66 \pm 1.17 | 0.016* |
| ICOS-CXCR5+CD154+ DP | 41.84 \pm 11.09 | 48.09 \pm 13.74 | 0.124 |
| ICOS+CXCR5- DP | 26.85 \pm 7.61 | 17.86 \pm 3.45 | <0.0001 |
| ICOS+CXCR5-CD154+ DP | 87.46 \pm 19.37 | 95.43 \pm 10.13 | 0.123 |
| ICOS-CXCR5- DP | 4.04 \pm 1.38 | 5.36 \pm 1.62 | 0.008* |
| ICOS-CXCR5- CD154+ DP | 41.00 \pm 10.52 | 46.08 \pm 12.56 | 0.172 |
| CD4-CD8- (DN) T cells (%) | | | |
| Total DN | 36.86 \pm 10.90 | 28.25 \pm 7.44 | 0.007* |
| ICOS+CXCR5+ DN | 15.21 \pm 4.95 | 17.90 \pm 4.14 | 0.074 |
| ICOS+CXCR5+CD154+ DN | 88.62 \pm 11.50 | 91.98 \pm 6.62 | 0.279 |
| ICOS-CXCR5+ DN | 6.97 \pm 1.70 | 12.19 \pm 3.61 | <0.0001 |
| ICOS-CXCR5+CD154+ DN | 34.47 \pm 9.38 | 34.43 \pm 10.28 | 0.989 |
| ICOS+CXCR5- DN | 36.28 \pm 9.50 | 31.09 \pm 7.83 | 0.071 |
| ICOS+CXCR5-CD154+ DN | 72.45 \pm 16.87 | 84.73 \pm 8.02 | 0.007* |
| ICOS-CXCR5- DN | 16.80 \pm 4.73 | 6.87 \pm 1.68 | <0.0001 |
| ICOS-CXCR5-CD154+ DN | 47.35 \pm 10.75 | 55.97 \pm 14.63 | 0.038* |

Comparison between the blood and colon tissue levels of double-positive (DP) and double-negative (DN) T cell subsets in UC patients

As shown in table 3, the total level of DP T cells was higher in tissue samples than in blood samples of UC patients ($p < 0.0001$). Active follicular DP T cells were higher in tissue samples ($p < 0.0001$), while the opposite was observed in the active non-follicular DP T cells ($p <$

0.0001). Higher CD154 surface expression levels were observed among activated follicular and non-follicular DP T cells in tissue samples ($p < 0.0001$).

The total level of DN T cells was lower in the tissue than in the blood of UC patients ($p < 0.0001$). On the contrary, active follicular and non-follicular DP T cells and their expression of CD154 were higher in tissues ($p < 0.0001$).

Table 3: Comparison of the levels of blood and colon tissue levels of double-positive (DP) and double-negative (DN) T cell subsets in UC patients

| Cells | Blood sample | Tissue sample | P value |
|----------------------------------|---------------|---------------|---------|
| Lymphocytes | 29.67 ± 5.46 | 44.72 ± 9.25 | <0.0001 |
| CD4+CD8+ (DP) T cells (%) | | | |
| Total DP T cells | 0.37 ± 0.11 | 23.40 ± 7.71 | <0.0001 |
| ICOS+CXCR5+ DP | 32.54 ± 9.11 | 72.62 ± 10.81 | <0.0001 |
| ICOS+CXCR5+CD154+ DP | 27.80 ± 5.67 | 98.21 ± 3.23 | <0.0001 |
| ICOS-CXCR5+ DP | 12.42 ± 3.61 | 2.85 ± 0.86 | <0.0001 |
| ICOS-CXCR5+CD154+ DP | 48.45 ± 13.85 | 41.84 ± 11.09 | 0.093 |
| ICOS+CXCR5- DP | 51.00 ± 15.28 | 26.85 ± 7.61 | <0.0001 |
| ICOS+CXCR5-CD154+ DP | 7.01 ± 2.36 | 87.46 ± 19.37 | <0.0001 |
| ICOS-CXCR5- DP | 23.99 ± 7.63 | 4.04 ± 1.38 | <0.0001 |
| ICOS-CXCR5-CD154+ DP | 40.32 ± 12.10 | 41.00 ± 10.52 | 0.844 |
| CD4-CD8- (DN) T cells (%) | | | |
| Total DN T cells | 50.38 ± 11.55 | 36.86 ± 10.90 | <0.0001 |
| ICOS+CXCR5+ DN | 1.95 ± 0.63 | 15.21 ± 4.95 | <0.0001 |
| ICOS+CXCR5+CD154+ DN | 22.57 ± 6.92 | 88.62 ± 11.50 | <0.0001 |
| ICOS-CXCR5+ DN | 20.24 ± 6.54 | 6.97 ± 1.70 | <0.0001 |
| ICOS-CXCR5+CD154+ DN | 7.10 ± 1.60 | 34.47 ± 9.38 | <0.0001 |
| ICOS+CXCR5- DN | 22.39 ± 7.25 | 36.28 ± 9.50 | <0.0001 |
| ICOS+CXCR5-CD154+ DN | 10.03 ± 3.31 | 72.45 ± 16.87 | <0.0001 |
| ICOS-CXCR5- DN | 26.61 ± 5.61 | 16.80 ± 4.73 | <0.0001 |
| ICOS-CXCR5-CD154+ DN | 16.54 ± 4.99 | 47.35 ± 10.75 | <0.0001 |

Comparison of the levels of DP and DN T cell subsets in blood and colon tissue of UC patients based on the disease severity assessed by the Mayo Score

Activated follicular DP and follicular DN T cells and their CD154 expression levels were greater in the blood and tissue of severe cases than in non-severe cases ($p = 0.018, < 0.0001, < 0.0001, 0.003$ in blood, and $0.002, 0.016, 0.001, 0.015$ in tissue, respectively).

Evaluation of the different T cell subsets as possible predictors of severity in blood and colon tissue

As shown in Table (4) and Figures (1) and (2), the Receiver Operating Characteristics (ROC) curve has been used to evaluate the accuracy of employing the level of activated follicular DP and DN T cells and activated follicular DP and DN T cells expressing CD154 in blood and tissue as potential predictors of severity in UC patients. All cells have shown good predictive efficiencies.

Table 4: Receiver operating characteristics (ROC) curve of follicular DP and follicular DN T cells in blood and tissue for prediction of disease severity in UC patients

| Blood T cell subsets | Cut-off | Sensitivity | Specificity | +PV | -PV | AUC |
|-----------------------|---------|-------------|-------------|-------|-------|-------|
| ICOS+CXCR5+ DP | > 25.3 | 100.00 | 87.50 | 93.3 | 100.0 | 0.920 |
| ICOS+CXCR5+CD154+ DP | > 24.5 | 92.86 | 100.00 | 100.0 | 88.9 | 0.964 |
| ICOS+CXCR5+ DN | > 1.7 | 92.86 | 100.00 | 100.0 | 88.9 | 0.996 |
| ICOS+CXCR5+CD154+ DN | > 19.4 | 91.67 | 100.00 | 100.0 | 88.9 | 0.979 |
| Tissue T cell subsets | Cut-off | Sensitivity | Specificity | +PV | -PV | AUC |
| ICOS+CXCR5+ DP | > 69.5 | 92.86 | 87.50 | 92.9 | 87.5 | 0.911 |
| ICOS+CXCR5+CD154+ DP | > 99.3 | 92.86 | 87.50 | 92.9 | 87.5 | 0.853 |
| ICOS+CXCR5+ DN | > 13.5 | 85.71 | 100.00 | 100.0 | 80.0 | 0.969 |
| ICOS+CXCR5+CD154+ DN | > 89.8 | 92.86 | 100.00 | 100.0 | 88.9 | 0.929 |

PV predictive value, AUC area under the curve




Fig. 1: Receiver operating characteristics (ROC) curve of follicular DP and follicular DN T cells in peripheral blood for severity prediction in UC patients. (A) ICOS+CXCR5+DP, (B) ICOS+CXCR5+CD154+DP, (C) ICOS+CXCR5+DN, (D) ICOS+CXCR5+CD154+DN




Fig. 2: Receiver operating characteristics (ROC) curve of follicular DP and follicular DN T cells in tissue for severity prediction in UC patients. (A) ICOS+CXCR5+DP, (B) ICOS+CXCR5+CD154+DP, (C) ICOS+CXCR5+DN, (D) ICOS+CXCR5+CD154+DN

DISCUSSION

Although the phenotype of CD4+ and CD8+ single-positive T cells has been the subject of numerous studies, little is known about the phenotype and functions of DP and DN T cells in autoimmune diseases^{15,16}, especially in UC patients.

Controversial findings regarding the function of the DP T cell subset have been published in the last decades.¹⁷ Previous research has demonstrated changes in the DP T cells in various disorders, including cancer, inflammatory/autoimmune diseases, and infectious diseases. Some authors reported a pro-inflammatory activity, while others showed a down-regulatory one. The current study revealed higher levels of DP T cells in colon tissues than in the patient's blood, especially the activated follicular subset with higher expression of CD154. In severe cases, active follicular DP T cells and those expressing CD154 were higher. These findings suggest that these cells may play a role in colon involvement and UC progression. Additionally, their elevated levels demonstrated good predictive efficiency for UC severity. Therefore, controlling these cells' expression may help develop novel UC therapeutic approaches. Additionally, prior research indicates that CD40L up-regulation produces harmful cytokines in IBD and that patients may benefit from blocking CD40-CD40L interactions.¹⁰

Meanwhile, in the peripheral blood, the overall percentage of DP T cells was higher in the UC patient's group compared with the control. However, UC patients had higher percentages of activated non-follicular DP T cells in their colon tissue and blood than in the controls. There were no significant differences in the follicular DP T cell levels between both groups. More research is required to fully understand the function of the DP T cell subset in the UC inflammatory process.

Research on murine intra-epithelial lymphocytes (IELs) indicated that CD4+CD8 $\alpha\alpha$ + DP T cells in the gut might carry out regulatory activities, as evidenced by their production of TGF- β and IL-10. These two cytokines reduce inflammation¹³. According to Wu *et al.*¹⁸, DPT cells may play a key suppressive role in producing autoantibodies in SLE.

On the other hand, DP T cells in HIV-infected subjects were found to produce high levels of the proinflammatory cytokines IFN- γ and TNF^{17,19,20}. Patients with Sjogren's syndrome and several autoimmune disorders like rheumatoid arthritis (RA) and multiple sclerosis (MS) have higher levels of DP T cells.²¹⁻²⁵ In some inflammatory diseases, the existence of DP T cells is also suggested as a predictor for severity. Peripheral DP cells in systemic lupus erythematosus (SLE) are related to an increased risk of developing renal impairment²⁶. Furthermore, DP T cell proliferation in RA is related to joint damage and

frequent therapy escalation²⁵. Graft versus host disease (GVHD) development is another example of DP T cell presence in inflammation. GVHD has been linked recently to establishing a DP T cell population that was not initially present in the graft²⁷.

Even though DN T cells account for a small fraction of the T-cell population, they are crucial in the pathogenesis of numerous diseases by regulating and suppressing essential inflammatory effector processes or inducing cell death and causing tissue damage⁷. Despite the lower levels of DN T cells in tissue than in the blood of UC patients, their levels in UC patient's tissues were significantly higher than in the control's tissues. Additionally, higher frequencies of activated follicular DN T cells with higher expression of CD154 were detected in colon tissue than in blood in UC patients. Their levels were also higher in the tissues and blood of severe cases. They showed good efficiencies in predicting UC severity, which might reflect their probable role in tissue damage and disease progression.

More research is required to understand how they influence the immunopathogenesis of UC. DN T cells are actively involved in chronic autoimmune inflammatory disorders, as evidenced by their tissue distribution and the effector cytokines they generate. Whether this population is a stable lineage of distinct subsets resembling the CD4+ T helper cell subset. To identify potential targets for interventional therapy, a deeper comprehension of the potential variability and flexibility of DNT cells is necessary²⁸.

It is commonly recognized that distinct lymphocyte subpopulations preferentially express and utilize distinct chemokine receptors for migration²⁹. According to Wiener *et al.*,³⁰ CXCR5 plays a crucial role in the development of lupus through regulating B cell and double-negative T cell trafficking, particularly in the pathophysiology of lupus nephritis in murine models and systemic lupus erythematosus (SLE). Patients with SLE have more DN T lymphocytes in their peripheral blood. DN T cells invade inflammatory tissue, including the kidneys, release proinflammatory cytokines, and stimulate the synthesis of immunoglobulins. In mouse lupus, CXCR5 deficiency changes immune cell trafficking³¹⁻³³. Furthermore, CXCL13 and its receptor CXCR5 have been linked to the pathophysiology of multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, primary Sjögren's syndrome, myasthenia gravis, and inflammatory bowel disease, according to recent investigations³⁴.

CONCLUSION

Levels of DP and DN follicular T cells are higher in the tissue of UC patients than in blood, with higher expression of CD154 in tissues. Levels of these cells are higher in more severe cases and show good efficiencies

in predicting disease severity. Further research is needed to assess whether these cells have a role in the inflammatory process in UC.

REFERENCES

1. Spiceland CM, Lodhia N. Endoscopy in inflammatory bowel disease: Role in diagnosis, management, and treatment. *World journal of gastroenterology*. 2018;24(35):4014-20.
2. Al-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. *Front Pharmacol* 2021;12:651415.
3. Zhang L, Ocansey DKW, Liu L, Olovo CV, Zhang X, Qian H. et al. Implications of lymphatic alterations in the pathogenesis and treatment of inflammatory bowel disease. *Biomed Pharmacother*. 2021;140:111752.
4. Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI. IBD immunopathogenesis: A comprehensive review of inflammatory molecules. *Autoimmunity reviews* 2017;16(4):416-26.
5. Overgaard Nana H, Jung Ji-Won, Steptoe Raymond J, Wells James W. CD4⁺/CD8⁺ double-positive T cells: more than just a developmental stage. *Journal of Leukocyte Biology*. Volume 97, Issue 1, January 2015: 97:31–38.
6. Parel Y, Chizzolini C. CD4+CD8+ double positive (DP) T cells in health and disease. *Autoimmun Rev*. 2004;3(3):215-220.
7. Brandt D, Hedrich CM. TCRαβ⁺ CD3⁺ CD4[−] CD8[−] (double negative) T cells in autoimmunity. *Autoimmun Rev*. 2018;17(4):422–30.
8. Juvet SC, Zhang L. Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions. *J Mol Cell Biol*. 2012;4(1):48–58.
9. Pabst O, Herbrand H, Bernhardt G, Förster R. Elucidating the functional anatomy of secondary lymphoid organs. *Current opinion in immunology*. 2004 Aug 1;16(4):394-9.
10. Liu Z, Colpaert S, D'Haens GR, Kasran A, Boer MD, Rutgeerts P, Geboes K, Ceuppens JL. Hyper expression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. *The Journal of Immunology*. 1999 Oct 1;163(7):4049-57.
11. James DL, Shaokun C, Lisa N, Gary RL, N Faten. Aberra, Jonas H. Ellenberg, Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis. *Inflammatory Bowel Diseases*. 1 December 2008;14:12:1660–1666.
12. Jeong Y, Jeon SR, Kim HG, Moon JR, Lee TH, Jang JY, Park S. The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis. *Intestinal research*. 2021;19(1): 62-70.
13. Okba AM, Amin MM, Abdelmoaty AS, Ebada HE, Kamel AH, Allam A. S, Sobhy OM. Neutrophil/lymphocyte ratio and lymphocyte/monocyte ratio in ulcerative colitis as non-invasive biomarkers of disease activity and severity. *Autoimmunity Highlights*. 2019;10:1-9.
14. Yamamoto-Furusho JK, Mendieta-Escalante E. A. Diagnostic utility of the neutrophil-platelet ratio as a novel marker of activity in patients with Ulcerative Colitis. *PLoS One*. 2020;15(4): e0231988.
15. Martin MD, Badovinac VP. Defining Memory CD8 T Cell. *Front. Immunol*. 2018: 9.
16. Samji T, Khanna KM. Understanding Memory CD8⁺ T cells. *Immunol. Lett*. 2017: 185: 32–39.
17. Chauhan N.K, Vajpayee M, Mojumdar K, Singh R, Singh A. Study of CD4+CD8⁺ double positive T-lymphocyte phenotype and function in Indian patients infected with HIV-1. *J. Med. Virol*. 2012: 84: 845–856.
18. Wu Y, Cai B, Feng W, Yang B, Huang Z, Zuo C, Wang L. Double positive CD4⁺ CD8⁺ T cells: key suppressive role in the production of autoantibodies in systemic lupus erythematosus. *Indian Journal of Medical Research*. 2014;140(4): 513-519.
19. Weiss L, Roux A, Garcia S, Demouchy C, Haeflner-Cavaillon N, Kazatchkine M.D, Gougeon M. Persistent expansion, in a human immunodeficiency virus-infected person, of V beta-restricted CD4+CD8⁺ T lymphocytes that express cytotoxicity-associated molecules and are committed to produce interferon-gamma and tumor necrosis factor-alpha. *J. Infect. Dis*. 1998: 178: 1158–1162.
20. Zou S, Tan Y, Xiang Y, Liu Y, Zhu Q, Wu S, Guo W, Luo M, Shen L, Liang K. The Role of CD4+CD8⁺ T Cells in HIV Infection With Tuberculosis. *Front. Public Health* 2022: 10: 895179.
21. Ferraccioli GF, Tonutti E, Casatta L, Pegoraro I, De Vita S, Sala P, Ravaioli T, Bartoli E. CD4 cytopenia and occasional expansion of CD4+CD8⁺ lymphocytes in Sjögren's syndrome. *Clin. Exp. Rheumatol*. 1996;14:125–130.
22. Wang S, Shen H, Bai B, Wu J, Wang J. Increased CD4+CD8⁺ Double-Positive T Cell in Patients with Primary Sjögren's Syndrome Correlated with Disease Activity. *J. Immunol. Res*. 2021: 2021: 6658324.
23. Ziaber J, Stopczyk D, Tchórzewski H, Chmielewski H, Baj Z, Paśnik J. Increased percentage of “double

- phenotype” form T lymphocytes in blood of patients with multiple sclerosis. *Neurol. Neurochir. Pol.* 2000; 34: 1137–1143.
24. Quandt D, Rothe K, Scholz R, Baerwald CW, Wagner U. Peripheral CD4CD8 double-positive T cells with a distinct helper cytokine profile are increased in rheumatoid arthritis. *PLoS ONE* 2014; 9: e93293.
 25. Nguyen P, Melzer M, Beck F, Krasselt M, Seifert O, Pierer M, Rothe K, Wagner U. Expansion of CD4+CD8+ double-positive T cells in rheumatoid arthritis patients is associated with erosive disease. *Rheumatology* 2022; 61:1282–1287.
 26. Chang K, Na W, Liu C, Xu H, Liu Y, Wang Y, Jiang Z. Peripheral CD4 +CD8 + double positive T cells: A potential marker to evaluate renal impairment susceptibility during systemic lupus erythematosus. *J. Biomed. Res.* 2022;37: 59–68.
 27. Hess N.J, Turicek D.P, Riendeau J, McIlwain S.J, Guzman E.C, Nadiminti K, Hudson A, Callander N.S, Skala M.C, Gumperz J.E. et al. Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology. *Sci. Adv.* 2023; 9: eadf0567.
 28. Li, Hao; Tsokos, George C. Double-negative T cells in autoimmune diseases. *Current Opinion in Rheumatology*. March 2021; 33(2):p 163-172.
 29. Ebert LM, Schaerli P, Moser B. Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. *Mol. Immunol.* 2005; 42 : 799-809.
 30. Wiener A, Schippers A, Wagner N, Tacke F, Ostendorf T, Honke N, Tenbrock K, Ohl K. CXCR5 is critically involved in progression of lupus through regulation of B cell and double-negative T cell trafficking. *Clinical and experimental immunology*, (2016). 185(1), 22–32.
 31. Crispin JC, Oukka M, Bayliss G. et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. *J Immunol.* 2008; 181:8761–6.
 32. Zhang Z, Kyttaris V.C, Tsokos G.C. The role of IL-23/IL-17 axis in lupus nephritis. *J Immunol.* 2009; 183:3160–9.
 33. Shivakumar S, Tsokos GC, Datta SK. T cell receptor alpha/beta expressing double-negative (CD4–/CD8–) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. *J Immunology*. 1989; 143:103–12.
 34. Pan Z, Zhu T, Liu Y, Zhang N. Role of the CXCL13/CXCR5 Axis in Autoimmune Diseases. published correction appears in *Front Immunol.* 2022 Oct 20;13:1061939. *Front Immunol.* 2022; 13:850998. Published 2022 Mar 4.